Micropeptides are capable of modulating insulin secretion, sensitivity, and mitochondrial function, and these regulatory sites may become potential therapeutic targets for improving cognitive function in AD patients (Potenza et al., 2021). This evidence concerns the gene INS and Alzheimer disease.